OpenPV Signal Explorer
FAERS disproportionality dashboard
← All drug classes
Drug class · FAERS comparison

Integrin Receptor Antagonist side effects compared: 3 drugs, 266,435 FDA adverse event reports

Class as assigned in the FDA label (Established Pharmacologic Class) · data 2026-09-14
How to read this page. Report counts are not incidence rates: a drug with more reports is usually older, more widely used or more publicised, not more dangerous. Signals are screened against each product's FDA label on its own page; a term flagged across most of a class usually reflects the shared mechanism or the shared patient population.

Members

DrugFAERS reportsSeriousDeath outcomeBoxed warningTop labeled signalsUnlabeled (unassessed)
Natalizumab (Tysabri)180,63031%5,103boxedMultiple sclerosis relapse; General symptom; Progressive multifocal leukoencephalopathyPrescribed underdose; Poor venous access
Vedolizumab (Entyvio, Entyvio Pen)85,58487%4,219–Colon dysplasiaFrequent bowel movements; Defaecation urgency
Natalizumab-Sztn (Tyruko)22196%4boxedMultiple sclerosis relapseMobility decreased

Class-wide signals (flagged in at least 2 of 3 members)

ReactionMembers flaggedMedian PRRReports (sum)In label
Multiple sclerosis relapse2/329.716,9182/2 members' labels

Member-specific signals (flagged in exactly one drug)

No strong single-member signals (n ≥ 50) in this class.

Common questions

Which integrin receptor antagonist has the most FDA adverse event reports?

Natalizumab has the most FAERS co-reports in this class (180,630), followed by Vedolizumab (85,584). Report volume tracks how widely and how long a drug has been used, and how much attention it has had, far more than its risk.

Which side effects are shared across integrin receptor antagonist drugs?

Reaction terms flagged in at least half of the 3 members include multiple sclerosis relapse. A term shared across a class usually reflects the shared mechanism (or the shared patient population) rather than one product.

Does a FAERS signal mean the drug causes the reaction?

No. These are disproportionality signals from voluntary reports with no denominator. Each is screened against the FDA label (known vs unlabeled) on the drug pages; causality needs temporality, dose-response, plausibility and trial or cohort evidence.

Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, seriousness and death counts from openFDA count queries. Generated 2026-10-08. Not medical advice.